Ortin Global Valuation

Is 539287 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 539287 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 539287's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 539287's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 539287?

Key metric: As 539287 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 539287. This is calculated by dividing 539287's market cap by their current revenue.
What is 539287's PS Ratio?
PS Ratio	28.2x
Sales	₹5.44m
Market Cap	₹153.44m

539287 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	27.7x
Enterprise Value/EBITDA	-3.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 539287's PS Ratio compare to its peers?

The above table shows the PS ratio for 539287 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.9x
524661 Welcure Drugs & Pharmaceuticals	0.4x	n/a	₹109.0m
524711 Vista Pharmaceuticals	8.6x	n/a	₹871.4m
524606 Beryl Drugs	0.7x	n/a	₹163.8m
531210 Colinz Laboratories	1.9x	n/a	₹132.3m
539287 Ortin Global	28.2x	n/a	₹153.4m

Price-To-Sales vs Peers: 539287 is expensive based on its Price-To-Sales Ratio (28.2x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does 539287's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.5x	n/a	US$90.98m
539561 Remedium Lifecare	0.07x	n/a	US$28.97m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$19.63m
531173 Syschem (India)	0.5x	n/a	US$18.80m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 539287 is expensive based on its Price-To-Sales Ratio (28.2x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 539287's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

539287 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	28.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 539287's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

11.6%

27.4%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

-0.4%

58.1%

Venus Remedies

₹4.0b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

-1.3%

-16.9%